NeoGenomics Company Profile (NASDAQ:NEO)

About NeoGenomics

NeoGenomics logoNeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NEO
  • CUSIP:
Key Metrics:
  • Previous Close: $8.33
  • 50 Day Moving Average: $8.10
  • 200 Day Moving Average: $8.01
  • 52-Week Range: $77,893,000.00 - $5.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 39.67
  • P/E Growth: 3.20
  • Market Cap: $648.85M
  • Outstanding Shares: 77,893,000
  • Beta: 1.27
  • Net Margins: -3.76%
  • Return on Equity: 3.18%
  • Return on Assets: 1.89%
  • Debt-to-Equity Ratio: 0.28%
  • Current Ratio: 2.50%
  • Quick Ratio: 2.35%
Additional Links:
Companies Related to NeoGenomics:

Analyst Ratings

Consensus Ratings for NeoGenomics (NASDAQ:NEO) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $10.50 (26.05% upside)

Analysts' Ratings History for NeoGenomics (NASDAQ:NEO)
DateFirmActionRatingPrice TargetDetails
9/8/2016Raymond James Financial Inc.Initiated CoverageOutperform$10.00View Rating Details
7/27/2016Benchmark Co.Boost Price TargetBuy$10.00 -> $12.00View Rating Details
7/27/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
7/9/2016Craig HallumReiterated RatingBuyView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00View Rating Details
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$11.00View Rating Details
10/26/2015William BlairReiterated RatingBuyView Rating Details
(Data available from 9/25/2014 forward)


Earnings History for NeoGenomics (NASDAQ:NEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)($0.01)$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NeoGenomics (NASDAQ:NEO)
Current Year EPS Consensus Estimate: $0.13 EPS
Next Year EPS Consensus Estimate: $0.21 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.01)($0.01)($0.01)
Q2 20161$0.01$0.01$0.01
Q3 20161$0.04$0.04$0.04
Q4 20161$0.05$0.05$0.05
(Data provided by Zacks Investment Research)


Dividend History for NeoGenomics (NASDAQ:NEO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NeoGenomics (NASDAQ:NEO)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 77.20%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.51View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.00View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.00View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.00View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.00View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.00View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.50View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.00View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for NeoGenomics (NASDAQ:NEO)
News IconLooking Ahead for NeoGenomics, Inc. (NASDAQ:NEO); Are These Shares Ready to Go Higher? - Frisco Fastball (NASDAQ:NEO) - September 22 at 6:02 PM
News IconPathogen Identification and Treatment Market by Technological Advances, 2016 – 2022 (NASDAQ:NEO) - September 22 at 11:09 AM logoForget Novavax, Buy These 4 Biotech Stocks Instead (NASDAQ:NEO) - September 16 at 6:05 PM
News IconLiquid Biopsy Market To Gain From Enhanced Demand In End-use Industries Till 2030: Grand View Research, Inc. (NASDAQ:NEO) - September 15 at 6:25 PM
News IconConsensus Estimates on Earnings & Stock Price in Focus for NeoGenomics, Inc. (NASDAQ:NEO) Shares - Frisco Fastball (NASDAQ:NEO) - September 14 at 10:38 AM logoNeoGenomics, Inc. (NASDAQ:NEO) Is Expected To Post EPS Of $0.01 - (NASDAQ:NEO) - September 14 at 10:38 AM logoBiotech Stocks Bounce Back in Monday Trading: 3 Picks (NASDAQ:NEO) - September 13 at 11:11 AM logoETF’s with exposure to NeoGenomics, Inc. : September 12, 2016 (NASDAQ:NEO) - September 12 at 6:03 PM
News IconHealth Discovery Corporation Announces Formation of Development Committee (NASDAQ:NEO) - September 12 at 10:59 AM logoHealth Discovery Corporation Forms Development Committee (NASDAQ:NEO) - September 12 at 10:59 AM logoETF’s with exposure to NeoGenomics, Inc. : September 2, 2016 (NASDAQ:NEO) - September 2 at 11:12 AM logoBrazil judge suspends operating license for Belo Monte hydrodam (NASDAQ:NEO) - September 1 at 6:19 PM
News IconShares Slipping Lower Over the Past Month: Neogenomics Inc. (NASDAQ:NEO) - Post News (NASDAQ:NEO) - September 1 at 9:33 AM
News IconCan the Crowd & Analysts Agree on NeoGenomics, Inc. (NASDAQ:NEO)? - Post News (NASDAQ:NEO) - August 23 at 10:49 AM logoNEOGENOMICS INC Financials (NASDAQ:NEO) - August 16 at 6:33 PM logoETF’s with exposure to NeoGenomics, Inc. : August 15, 2016 (NASDAQ:NEO) - August 15 at 6:41 PM logoEarnings Surprise In Focus: NeoGenomics, Inc. (NASDAQ:NEO) - Investor Newswire (NASDAQ:NEO) - August 14 at 10:54 AM logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:NEO) - August 10 at 6:51 PM logoNEOGENOMICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:NEO) - August 5 at 6:36 PM logoETF’s with exposure to NeoGenomics, Inc. : August 4, 2016 (NASDAQ:NEO) - August 4 at 6:46 PM logoNeoGenomics, Inc. breached its 50 day moving average in a Bearish Manner : NEO-US : August 2, 2016 (NASDAQ:NEO) - August 2 at 11:12 AM logoForm 4 NEOGENOMICS INC For: Jul 28 Filed by: HIPP RAYMOND R - (NASDAQ:NEO) - July 30 at 5:48 PM
News IconPathogen Identification and Treatment Market : Recent Industry Trends and Projected Industry Size by 2016 – 2022 (NASDAQ:NEO) - July 29 at 6:34 PM logoICON : How These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON (NASDAQ:NEO) - July 29 at 9:26 AM logoHow These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON (NASDAQ:NEO) - July 29 at 9:26 AM logoNeoGenomics Shares Nearing Full Valuation In BTIG's View (NASDAQ:NEO) - July 28 at 9:37 AM
News IconNeoGenomics reports revenue rose almost 160 percent in second quarter - Naples Daily News (NASDAQ:NEO) - July 27 at 6:44 PM
News IconNeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016 (NASDAQ:NEO) - July 27 at 9:24 AM
News IconNeoGenomics reports revenue rose almost 160 percent in second quarter (NASDAQ:NEO) - July 27 at 9:24 AM logoEdited Transcript of NEO earnings conference call or presentation 26-Jul-16 3:00pm GMT (NASDAQ:NEO) - July 26 at 7:02 PM logoBRIEF-NeoGenomics Q2 adjusted earnings per share $0.04 (NASDAQ:NEO) - July 26 at 6:43 PM logoNEOGENOMICS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:NEO) - July 26 at 6:43 PM logoNEOGENOMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:NEO) - July 26 at 11:05 AM logoBRIEF-NeoGenomics Q2 adjusted earnings per share $0.04 - Reuters (NASDAQ:NEO) - July 26 at 9:38 AM logoNeoGenomics Inc.: NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in ... - The Wall Street Transcript (NASDAQ:NEO) - July 26 at 9:38 AM logoMargins Are Key For NeoGenomics In Q2 2016 - Seeking Alpha (NASDAQ:NEO) - July 26 at 9:38 AM logoNeoGenomics reports 2Q loss (NASDAQ:NEO) - July 26 at 7:27 AM logoInvestor Calendar Invites You to the NeoGenomics Second Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday, July 26, 2016 (NASDAQ:NEO) - July 25 at 4:10 PM
News IconNeoGenomics, Inc. (NASDAQ:NEO): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:NEO) - July 22 at 9:21 AM logoBrokers Issue Average Price Target Of 8.50 On NeoGenomics, Inc. (NEO) - Fiscal Standard (NASDAQ:NEO) - July 22 at 9:21 AM
News IconIs Buying All-time Stock Like NeoGenomics, Inc. a Winning Strategy? - Consumer Eagle (NASDAQ:NEO) - July 22 at 9:21 AM logoNeoGenomics, Inc. : half-yearly earnings release (NASDAQ:NEO) - July 21 at 6:42 PM logoNew Broker Ratings For NeoGenomics, Inc. (NEO) - FTSE News (NASDAQ:NEO) - July 20 at 9:20 AM
News IconEquity Roundup: Stock Performance Focus on NeoGenomics, Inc. (NASDAQ:NEO) - Press Telegraph (NASDAQ:NEO) - July 20 at 9:20 AM
News IconShare Performance Summary for: Neogenomics Inc. (NASDAQ:NEO) - Press Telegraph (NASDAQ:NEO) - July 19 at 9:55 AM logoNeogenomics Inc versus Pacific Biosciences of California Inc Head to Head Compare - CML News (NASDAQ:NEO) - July 19 at 9:55 AM logoNeoGenomics, Inc. – Value Analysis (NASDAQ:NEO) : July 18, 2016 (NASDAQ:NEO) - July 18 at 4:04 PM
News IconShares Moving Down on the Week: Neogenomics Inc. (NASDAQ:NEO) - Engelwood Daily (NASDAQ:NEO) - July 17 at 5:49 PM
News IconNeogenomics Incorporated (NASDAQ:NEO) Sellers Increased By 8.74% Their Shorts - Consumer Eagle (NASDAQ:NEO) - July 17 at 10:40 AM
News IconNeoGenomics, Inc. (NASDAQ:NEO) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:NEO) - July 15 at 11:13 AM


NeoGenomics (NASDAQ:NEO) Chart for Sunday, September, 25, 2016

Last Updated on 9/25/2016 by Staff